Novavax Inc NVAX

$8.52 -0.24 (-2.68%)

Valuation

Market cap
1,445,479,000
Revenue TTM
$1,123,480,000
Net income TTM
$440,300,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
39.19%
Debt to equity
-1.35

Trading

Volume
4,643,000
Avg volume
7,048,662
Day's range
$8.35 – $8.78
Shares out
165,009,000
Stochastic %K
6%
Beta
2.65
Analysts
Moderate Buy
Price target
$13.90

Price

Company profile

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Ser...

Show more

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Industry
Biotechnology
Sector
Healthcare
Phone
240 268 2000
Website
https://www.novavax.com
Address
21 Firstfield Road, Gaithersburg, United States

Latest news

Stocktwits

OnePunchMan___ Nov 14, 10:12 PM
$NVAX next year will be different
0 replies
tatanka9 Nov 14, 9:57 PM
$NVAX Why another Bio comapny would put Jacob’s on their BOD is unbelievable? JJ has done nothing for NVAX but drive the stock price down further since his arrival. If this was sports they would have fired his ass along time ago.
0 replies
Pissed_of_retards2 Nov 14, 9:18 PM
$NVAX there is bloodbath incrypto. hopefully nvax will do better next week
1 replies
ddirk Nov 14, 6:40 PM
$NVAX TRump finally made America great Again, by lossing the house and senate back to democrats how will try to cleanse things up AGAIN!!!
2 replies
LaurenM21 Nov 14, 5:30 PM
$NVAX Remember when the pitch was Sanofi taking 20–30% COVID share? Management quietly buried that thesis, and it is another "learning" year after learning year: - Sanofi did ~$30M in Q3 Nuvaxovid sales, so just $6M in royalties to NVAX (vs. $76M in Q3 R&D/SG&A) - Profitability pushed to 2029 waiting on $225M launch milestone and sub-teen combo royalties, giving up standalone Nuvaxovid hopes Baggies still waiting for triple digits on these dismal numbers! Stock is fairly valued between $8-16. It'll take a miracle and another pandemic to breakout. Accept reality for those who bought the triple digits, and take advantage of trading the current price range to regain your losses.
1 replies
Biotechlineup Nov 14, 5:24 PM
$SLS $NVAX FYI, IF Matrix M was swapped out as the adjuvant it would triple the efficacy and lower Reactogencity. Not happening of course that would mean an entirely new trial. For SLS , Here’s the bottom line issue, the control arm doesn’t have a known historical comparator. It’s not one well defined protocol that you can absolutely use as a number to calculate an end point Hazard ratio. Best available option and open label design leaves multiple variables. We just don’t know how long the OS for the control arm is. We shall see. Good Luck everyone.
7 replies
marketlimit Nov 14, 3:03 PM
$NVAX LMAO… garbage. $6 soon then $4
1 replies
wintogether Nov 14, 2:51 PM
$NVAX approaching zero gain for the year just in time for yearly tax loss harvesting!
2 replies